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Introduction
Th   e cure of diseases or at least an abatement of symptoms 
are the core aims of therapeutic medicine, and we might 
soon witness the transition from today’s abatement to 
tomorrow’s cure with regard to the quality of disease 
remission in the ﬁ   eld of rheumatic conditions, with 
rheumatoid arthritis (RA) as one of the most frequent 
entities. At present, achieving complete remission is the 
ultimate aim, at least for patients with recently diagnosed, 
early RA. Th   e reduction of clinical disease activity below 
a disease activity score of 2.6 when evaluating the 28 
relevant joints (DAS28), as well as the exclusion of still 
remaining clinically silent synovial inﬂ  ammation,  are 
considered to be the principal goals of current 
rheumatologic treatment concepts [1]. In cases with 
longer histories and at later stages of disease, however, 
the cutoﬀ    level for individually acceptable residual 
disease activity might have to be further deﬁ  ned together 
with the patient, and on the basis of this, individual 
stage-adapted medication evaluated continu  ously in 
close agreement with the patient [1,2].
Past pharmacologic options used to induce remission 
from RA included chrysotherapy, which became the ﬁ  rst 
established ‘gold’ standard. In 1928, Jacques Forestier had 
already started to use gold salts therapeutically in France, 
assuming an infectious factor in RA, which was in the 
tradition of Robert Koch’s evaluation of gold compounds 
against pure cultures of Mycobacterium tuberculosis [3]. 
Gold salts, however, were just one drug amongst a grow-
ing number of long-acting, remission-inducing agents 
showing only slow action in decreasing the inﬂ  ammatory 
activity of RA. Owing to this mode of action, they have 
been termed ‘second-line’ medication, also known as 
disease-modifying anti-rheumatic drugs (DMARDs); 
apart from gold salts, these also include medications such 
as azathioprine, chloroquine and hydroxychloroquine 
(HQ), cyclosporin A (CsA), cyclophosphamide, leﬂ  uno-
mide (LEF), metho  trexate (MTX), and sulfasalazine 
(SSZ). Th   e mechanisms of action of some of these drugs 
are still not fully deﬁ  ned, but they are likely to involve an 
overlap between anti-inﬂ  ammatory, immunosuppressive 
and cytotoxic proper  ties. Nonetheless, only DMARDs 
may signiﬁ  cantly slow, stop or even reverse the damage 
arising from chronic inﬂ  ammation in cartilage or bone, 
as shown in an in vitro study on human chondrocytes in 
alginate cultures [4], for example, as well as in clinical 
trials implementing radio  graphic follow-up of patients 
(see ‘Current reper  toire, proﬁ  les and clinical evidence for 
biologics in RA’ below). However, although DMARDs may 
slow radio  graphic progression, data also illustrate that 
progression can continue despite clinical disease control 
or remission [5].
First-line non-steroidal anti-inﬂ  ammatory  drugs 
(NSAIDs) and steroids, in contrast, more rapidly inhibit 
local inﬂ  ammatory symptoms but have only little to no 
long-lasting eﬀ  ects on the systemic aspects of RA, as 
reﬂ  ected by increased erythrocyte sedimentation rates or 
elevated levels of C-reactive protein. Th  erefore,  systemic 
signs of inﬂ  ammatory rheumatic conditions that patients 
may complain of - for example, loss of eﬃ   ciency, lassitude 
or weight reduction - are not improved by non-selective 
cyclooxygenase inhibitors, such as diclofenac, ibuprofen, 
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© 2010 BioMed Central Ltdnaproxen, piroxicam, meloxicam, indometacin or ace-
meta  cin, nor by the selective cyclooxygenase-2 inhibitors 
celecoxib or etoricoxib.
Members of the so-called biologics, formally classiﬁ  ed 
as a distinct subgroup within the DMARDs, form part of 
a speciﬁ  c therapeutic strategy targeting pro-inﬂ  am  ma-
tory key cytokines and cellular functions that have 
deleterious eﬀ   ects during the course of RA. Current 
options include not only several agents against TNF-α, 
but also compounds directed against IL-1 or IL-6 and 
modulators of B-cell or T-cell activity. Since biologics are 
known for their potential to abolish disease progression 
and persistent residual activity, it is not unreasonable to 
alternatively call them disease-controlling anti-rheumatic 
drugs [6].
Most importantly, the ongoing developments in this 
ﬁ  eld require a thorough knowledge of the properties and 
eﬀ  ects the currently available repertoire of target-speciﬁ  c 
biological agents may display in the treatment of RA. 
Th   is review refers to the recent clinical evidence for the 
use of diﬀ  erent biological therapies in RA, discusses their 
eﬃ   cacy and safety proﬁ  les and tries to deﬁ  ne in which 
situations their administration may prove beneﬁ  cial for 
the patient.
General considerations when designing a 
patient-oriented treatment plan
Many factors contribute to the speciﬁ  c treatment strategy 
used in RA. Data derived from controlled clinical trials 
form the prerequisite on which the status of approval, the 
approved indications and also the availability of a certain 
substance may prompt the treating physician to consider 
it within his or her repertoire based on his or her 
available knowledge and experience in the diagnosis, 
treatment and assessment of RA. Since biological sub-
stances show not negligible proﬁ   les of possible side 
eﬀ  ects and may sometimes even cause serious compli-
cations, the reasonable use of biological agents also 
requires especial awareness of their respective eﬃ   cacies 
versus toxicities. All individual patients or their repre-
sentatives should therefore be provided with any 
information needed such that they are fully enabled to 
estimate the risk-beneﬁ  t analysis themselves, especially 
as patients diﬀ  er in their risk for and expression of these 
side eﬀ  ects as well as in the clinical presentation of their 
disease. It is of critical importance to consider individual 
comorbidities regarding the cardiovascular system, pul-
mo  nary, hepatic and nephrologic status, hemato-
oncologic alterations as well as neurological conditions 
and individual risk for infections. Th  e duration of the 
existing RA disease course, previous therapies, and the 
duration until a medication takes eﬀ   ect, its anti-
inﬂ  ammatory properties, its eﬃ   cacy on the deferment of 
erosions, the mode of application, and inter  actions with 
co-medication form central elements of which the 
treating physician has to be aware. Age, gender, desire for 
children as well as individual employment situation 
further contribute to the decision for or against a certain 
medication [1].
Th  e actual state of the disease should be recorded 
before initiating a regimen; it is important to evaluate 
tender and swollen joint counts, general disease activity 
as considered by both physician and patient, the intensity 
of pain as assessed by visual analogue scales, the duration 
of morning stiﬀ   ness, functional disability assessed by 
suitable questionnaires, as well as the erythrocyte sedi-
men  tation rate and the level of C-reactive protein [7]. 
Predictors for the erosive character of the individual 
disease course may not only be given by the existing 
duration of disease, but also by the number of aﬀ  ected 
joints, the involvement of carpi, metacarpo-phalangeal, 
metatarso-phalangeal and proximal interphalangeal 
joints, the presence of anti-cyclic citrullin peptide anti-
bodies and rheumatoid factors, the ultrasound-measured 
intensity of synovialitis, the detection of bone marrow 
edema by magnetic resonance imaging, and early erosive 
events detected with conventional X-ray analysis [7].
Several validated measures can be employed to evaluate 
the response to treatment while continuously following 
patients over time. Th  ese may include the Disease 
Activity Score (DAS), the Simpliﬁ   ed Disease Activity 
Index (SDAI), the Clinical Disease Activity Index (CDAI), 
the Health Assessment Questionnaire Disability Index 
(HAQ-DI), various visual analogue scales, Likert scales of 
global response or pain as measured by the patient or the 
physician, as well as other validated instruments of pain 
measurement for individual patient care. Th   e number of 
tender and swollen joints and laboratory data should also 
be re-evaluated to obtain a complete picture of the 
therapeutic suitability and a sense of the need for possibly 
relevant modiﬁ   cations according to the individual 
patient’s status [8].
Current repertoire, profi  les and clinical evidence 
for biologics in rheumatoid arthritis
TNF-blocking agents
At present, ﬁ  ve TNF-blocking agents are available and 
approved for use in RA: etanercept, adalimumab, inﬂ  ixi-
mab, certolizumab and golimumab. Whereas etanercept, 
adalimumab and certolizumab are approved as mono-
therapy for RA, inﬂ   iximab and golimumab are only 
approved in combination with MTX. As monotherapy, 
TNF-blocking agents have proven eﬃ   cacy  in  patients 
with limited response to MTX [9]. However, combination 
of a TNF blocker with MTX yields better results than 
using either substance alone [10,11]. Moreover, 
preliminary data derived from comparative studies show 
that using MTX together with a TNF inhibitor might be 
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Nonetheless, TNF inhibitors may also be used in 
conjunction with DMARDs other than MTX - for 
example, with leﬂ  unomide or sulfasalazine - according to 
individual patients’ needs.
Although TNF inhibitors exhibit diﬀ  erences in their 
composition and pharmacokinetic and pharmaco-
dynamic properties, no evidence suggests that any of 
these agents should be used prior to any other or that one 
TNF blocking agent is more eﬀ  ective than any other in 
RA. Administering TNF-blocking agents up to the maxi-
mum approved dose for RA may evoke a response within 
2 to 4 weeks in some patients, but a signiﬁ  cant ameliora-
tion of disease should be seen within 12 to 24  weeks, 
leading to a documentable improvement in clinical and 
laboratory parameters. In this case, the treat  ment should 
be continued according to the physical and patient-
oriented measures.
Increasing the dose or reducing the intervals of 
administration may have additional beneﬁ  t.  When 
achieving remission or dealing with a low disease activity, 
an ongoing therapeutic eﬀ  ect may be sustained success-
fully despite a lowering of the dose [13]. In contrast, 
when failing to evoke any response, continued adminis-
tration of a TNF inhibitor should be appraised critically. 
A loss of response to TNF blockers can occur, but this 
does not necessarily preclude a response to another 
substance, since time and again patients have been 
switched successfully from one compound to another 
[14]. However, it is possible that patients who fail to 
respond to a ﬁ  rst TNF inhibitor could also fail to respond 
to a second one [8]. Th   e same is true for tolerance of the 
medication, although patients may show a response to it. 
Even when not displaying a clinical response, TNF-
blocking agents were shown to slow or even to stop 
radiographic progression of RA [15]. Of note, improved 
combined clinical and radiological outcomes can be 
achieved using a combination of both a TNF blocker and 
a traditional DMARD.
Considering the safety proﬁ   le of TNF inhibitors in 
general, treating physicians should not only be aware of 
possible complications linked to infections, malignancies, 
and the cardiovascular and pulmonary systems, but 
should also be familiar with haematological, neurological 
and hepatic symptoms as well as with the risk for 
autoimmune-like reactions and injection site reactions or 
adverse events during pregnancy.
Regarding infections, tuberculosis (TBC) represents a 
major risk when being treated with TNF blocking agents. 
Th   is implies both an increased susceptibility to TBC and 
the reactivation of latent TBC. Administration of 
corticoids also increases the risk. To date, no studies have 
made head-to-head comparisons of TNF inhibitors so no 
instructive data are available for the incidence of 
reactivation of latent TBC. However, clinical presentation 
of active cases may be atypical during administration of 
TNF-blocking agents [16]. Furthermore, not all instances 
of mycobacterial infection may be due to M. tuberculosis, 
as  Mycobacterium avium and others also account for 
reactivated disease [17]. Nevertheless, it is recommended 
to screen patients for latent TBC before initiating a 
therapeutic TNF blockade, as well as to evaluate any 
history of a potential prior exposure to mycobacteria 
[18]. It is appropriate to use tests such as the tuberculin 
skin test or assays measuring interferon-γ release, which 
have higher speciﬁ   city for detecting latent TBC and 
could thus prevent false positive results due to a bacillus 
Calmette-Guérin (BCG) vaccination in the past [19]. 
Th   ere is currently no consensus about when to start TNF 
block  ade after initiating treatment for latent TBC. 
Similarly, care has to be taken in the context of non-
tuberculous mycobacteria [20], listeriosis [21], coccidio-
mycosis [22] and histoplasmosis [23]. Accordingly, 
medication with TNF-blocking agents should not be 
performed in the context of serious or opportunistic 
infections or of septic complications, such as septic 
arthritis, infected prostheses, acute abscesses or osteo-
myelitis, as some studies indicated that certain sites may 
show serious infections more frequently, including the 
skin, soft tissues and joints [24]. Th   e incidence of serious 
infections is even higher when using a TNF-blocking 
agent in combination with anakinra (ANR) or abatacept 
(ABC) [25,26]. Th   erefore, the combination of two 
biological agents still remains a therapeutic challenge.
Care has to be taken in patients with chronic viral 
hepatitis B and C when using TNF-blocking agents. 
When hepatitis B infection is known of before treatment, 
use of TNF blockers should be considered only in excep-
tional cases after adequate treatment of the virus [27]. If 
the infection is diagnosed during the use of a TNF 
inhibitor, prophylactic antiviral therapy could be con-
sidered. In contrast, data for hepatitis C did not show any 
increased incidence of toxicity during TNF inhibitor 
treatment [27,28].
With regard to vaccination, TNF-blocking agents 
usually do not have any adverse eﬀ  ect on the synthesis of 
protective antibodies in the case of inﬂ  uenza vaccines 
despite a slight decrease in the titre of response, 
especially when used in combination with MTX [29]. 
Nevertheless, application of live attenuated vaccines is 
not recommended.
No signiﬁ  cant evidence is given for the development of 
solid malignancies during anti-TNF therapy, as analyses 
reporting a higher rate of solid tumours are counter-
balanced by studies that do not support this hypothesis 
in patients undergoing TNF blockade in comparison to 
matched controls. In general, however, the incidence of 
lymphoma was been found to be higher in chronic 
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increased risk for malignant lymphomas, especially non-
Hodgkin’s lymphoma, in RA patients in contrast to the 
general population has been reported [31]. Th  erefore,  the 
occurrence of malignancies should be surveyed in RA 
patients being treated with TNF blockers.
Results on the incidence of heart failure in patients 
with RA receiving TNF inhibitors are conﬂ  icting [32]. 
Also, TNF inhibitor treatment has been associated with a 
surprising eﬀ  ect on lipid metabolism [33] and rare cases 
of interstitial lung disease [34]. Additionally, central and 
peripheral demyelinating syndromes may occur [35]. 
Although autoantibody formation, such as antinuclear 
antibodies, is not uncommon with TNF blockade, 
associated clinical conditions are rare, but might be seen 
as antiphospholipid and lupus-like syndromes [36,37]. 
Injection-site reactions due to TNF administration occur 
with mild to moderate intensity [38]. Safety data for TNF 
inhibitor treatment during pregnancy are incomplete. 
Whether anti-TNF therapy should be stopped during 
pregnancy or whether continued administration is safe 
and without risk of fetal loss or miscarriages and asso-
ciation with a VACTERL syndrome (vertebral/anal/
cardiac abnormalities, tracheo-esophageal ﬁ  stulation, 
esophageal/renal/limb defects) is not clear at present 
[39].
Rituximab
Rituximab (RIX) is a chimaeric anti-CD20 monoclonal 
antibody originally approved for the treatment of CD20+ 
B-cell non-Hodgkin’s lymphoma and chronic lympho-
cytic leukaemia. For RA, RIX has been approved for the 
treatment of moderate to severe forms together with 
MTX in patients with an inadequate reponse to at least 
one TNF-blocking agent, or when TNF blockade is 
inappropriate, respectively [40,41]. In these patients, RIX 
is able to inhibit radiographic progression [42]. However, 
RIX may also be used in conjunction with DMARDs 
other than MTX or as monotherapy [43].
RIX can be given intravenously as two 1,000 mg 
infusions 2 weeks apart under support of 100 mg pred-
nisolone equivalent. Th  is remains the labelled dose, 
although two 500 mg doses have also been evaluated and 
demonstrated to provide equivalent clinical eﬃ   cacy [40]. 
Signiﬁ  cant improvements in signs and symptoms of RA 
have been observed after 8 to 16 weeks [44,45], with 
better responses in rheumatoid factor-positive and anti-
cyclic citrullin peptide antibody-positive patients and 
DMARD and TNF non-responders [41,46]. Repeated 
treatment courses each consisting of two infusions given 
2 weeks apart are eﬀ   ective in previously responsive 
patients [47], with each course being given no earlier 
than 16 weeks after the previous one. Whether re-
treatment of initial non-responders, possibly representing 
a diﬀ  erent patho  genetic subset of RA, is eﬀ  ective remains 
to be determined [48].
Th  e most frequent adverse event with RIX is an 
infusion reaction, but this is more often seen with the 
ﬁ  rst application of each course and is usually less promi-
nent with all subsequent infusions and can be prevented 
by the adequate use of intravenous cortico  steroids.
Before treatment with RIX, patients should be 
evaluated for a history of hepatitis B infection, since 
reactivation of hepatitis B was reported in patients who 
were treated with RIX due to non-Hodgkin’s lymphoma 
but received additional chemotherapy [49].
With regard to infections, not enough data are available 
to clearly determine the need for TBC screening before 
initiating RIX treatment. Th  erefore, the treating physi-
cian has to be aware of possible (re-)occurrences of TBC 
during therapy. In general, RIX is contraindicated in the 
presence of serious and opportunistic infections. Without 
these pre-existing infections, a slight increase in 
infectious events was found during RIX administration at 
a dose of 2 × 1,000 mg in comparison to placebo [50].
Th  e detailed role of B cells in RA remains to be 
elucidated because a more complete depletion of the 
peripheral CD20+ subpopulation following treatment 
with RIX was not consistently predictive for achieving or 
maintaining a clinical response in RA patients, suggesting 
that the timing of re-treatment should rather be based on 
disease activity than repletion of peripheral B cell levels 
[51]. As a consequence of B-cell depletion, any 
vaccinations desired by the patient (for example, for 
preventing inﬂ   uenza and pneumonia) should be given 
before treat  ment, although indicated vaccinations during 
treatment except for with live attenuated ingredients 
should still be given despite a lowered response [49].
Although no evidence underlines the association of 
RIX with an increased incidence of solid malignancies in 
RA, vigilance for this seems appropriate. Neurological 
complications, such as progressive multifocal leuco-
encepha  lo  pathy, remain a very rare event, but have been 
reported in cases of RA treated with RIX [52]. Th  e  same 
is true for unclear associations of psoriasis with RIX 
treatment [53]. Most cases of progressive multifocal 
leucoencephalopathy, however, were in patients who also 
had established risk factors for it.
Abatacept
Abatacept (ABC) is a fusion protein consisting of the 
extracellular portion of human cytotoxic T-lymphocyte 
antigen 4 (CTLA-4) and the Fc domain of IgG1. It binds 
to both CD80 and CD86 on antigen-presenting cells and 
interrupts the co-stimulatory eﬀ  ect via CD28 on T cells.
It is approved both as monotherapy and in combination 
with DMARDs for moderate to severe adult RA and 
polyarticular juvenile idiopathic arthritis. Use of ABC 
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more non-biological DMARDs and a failure of at least 
one TNF-blocking agent [54,55]. Direct switching to 
ABC after anti-TNF therapy can be performed without 
the need for a washout [56].
ABC is given intravenously at doses of 8 to 10 mg/kg 
body weight: 500 mg for patients <60 kg, 750 mg for 
patients 60 to 100 kg, and 1,000 mg for patients >100 kg, 
at weeks 0, 2 and 4 and then every 4 weeks. Some patients 
begin to respond within 2 to 4 weeks according to 
American College of Rheumatology criteria, and most 
individuals respond within 12 to 16 weeks after treatment 
initiation. Improvement may continue for up to 1 year, 
and increased inhibition of radiographic progression may 
occur even in the second year [57]. Th  e  eﬃ   cacy of ABC is 
similar to that of inﬂ  iximab 3 mg/kg, but there is a lower 
number of serious complications [58].
Th  e use of ABC in patients with chronic obstructive 
pulmonary disease led to more serious lower respiratory 
tract infections than placebo treatment [8]. Th   e risk for 
reactivation of latent TBC or developing new disease 
during ABC treatment has not been evaluated. In all 
phase III trials, patients were still enrolled despite a 
positive tuberculin skin test and being treated for latent 
TBC [8]. Combination of ABC with TNF blockers is not 
recommended due to an elevated risk for serious 
infections [26,59]. As with TNF blockers, live vaccines 
should not be given during or up to 3 months after ABC 
treatment. Evaluation of the risk for increases in 
neoplasm formation is still to be done.
Anakinra
Anakinra (ANR) is a recombinant protein identical to the 
physiologic IL-1 receptor antagonist (IL-1Ra), with the 
exceptions of having an additional methionine residue 
and lacking glycosylation. Approved for use in RA, ANR 
can be applied for active diseases as monotherapy or in 
combination with MTX at dosages of 100 mg per day 
subcutaneously after appropriate trials of non-biological 
DMARDs [60,61]. Of important note, however, addition 
of ANR to anti-TNF therapy is not recommended due to 
increased rates of serious adverse events [25,62].
ANR signiﬁ  cantly improves signs and symptoms of RA 
and is able to slow radiographic progression [60,62]. 
Ongoing use of ANR should be re-evaluated after 
16 weeks without any improvement. ANR administration 
should not be considered or continued in patients with 
serious infections as bacterial infections were more often 
observed in patients treated with ANR than with those 
treated with non-biological DMARDs [63]. Injection site 
reactions comprise the most frequent adverse event, with 
71% of patients receiving ANR versus 28% receiving 
placebo experiencing an injection site reaction according 
to a recent systematic analysis [64]. Since the eﬃ   cacy 
demonstrated in trials was modest and lower than for 
other biological agents, the margin of beneﬁ  t seems to be 
smaller [64,65]. Th  us, the exact position and value of 
ANR in the therapy of RA have to be further deﬁ  ned by 
ongoing long-term observational studies.
Tocilizumab
Tocilizumab (TOZ) is a humanized monoclonal anti-IL-6 
receptor antibody. It is administered intravenously in 
monthly dosages of 4 or 8 mg/kg body weight and is 
approved for moderate to severe active RA in combi-
nation with MTX or as a monotherapy in incomplete 
responders to DMARDs or TNF-blocking agents, where 
it can reduce the signs and symptoms of disease [66,67]. 
Note that in the US, TOZ does not have a before TNF 
indication, in contrast to its EU status. Th  e onset of 
response might occur after just 2 to 4 weeks in some 
cases, but TOZ might also take eﬀ  ect only after up to 
24 weeks.
Infusion site reactions to a serious extent are quite rare. 
Other speciﬁ  c side eﬀ  ects are increases in fasting plasma 
lipids, such as total cholesterol, low-density lipoprotein 
and triglycerides, which may have to be treated with 
statins [68-70]. Th  ere was no signiﬁ   cant increase in 
cardiovascular or cerebrovascular events for at least up to 
1.5 years of median follow-up in one study [68]. TOZ 
should be used with caution in patients with a history of 
intestinal ulceration or diverticulitis because perito-
nitides, lower gastrointestinal perforations, ﬁ  stulae, and 
intraabdominal abscesses have been documented in trials 
of 6-months’ duration [67]. In addition, there were more 
cases of transient neutropenia early after infusion in 
TOZ-treated patients than in controls receiving placebo 
[69]; thus, blood counts should be monitored regularly.
Although there is no evidence for serious liver 
aﬀ  ections or failure provoked by TOZ, organ function 
should also be evaluated at regular intervals due to the 
frequency of slight and often transient increases in 
aminotransferases [69]. An association of TOZ treatment 
with higher frequencies of neoplasm formation has not 
been proven so far. Moreover, the rate of serious 
infections did not increase signiﬁ   cantly in the studies 
performed, but similar care as with other biologics might 
be necessary when administering TOZ in patients with 
pre-existing serious or opportunistic infections, espe-
cially as few data convincingly refer to the management 
of TBC in this context because no such patients have 
been included in the studies. Links to viral infections 
such as with herpes zoster also still have to be conﬁ  rmed. 
Th  is is also the case for vaccinations against inﬂ  uenza, 
which might be safe and eﬀ  ective despite TOZ treatment, 
although live vaccines should not be given.
In summary, more detailed safety data addressing the 
infectiological, immunological, neoplastic, cardiovascular 
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gathered by upcoming extension studies.
Table 1 summarizes the dosages and mode of appli-
cation of the biologics currently approved for the 
treatment of RA.
Combining the evidence into possible 
‘standardized’ pharmacologic procedures
In the context of the safety, eﬃ   cacy,  indications  and 
administration-related proﬁ   les of biological agents as 
well as patient-related treatment criteria that should be 
considered before and during each treatment regimen, 
this section suggests a possible, non-dogmatic standard-
ized practical algorithm for a pharmacological treatment 
strategy in patients with RA. However, despite inter-
nationally disposable results of sometimes even long-
term observations during clinical studies, national prefer-
ences may lead to diﬀ  erent procedures. Nonetheless, the 
following procedure, which is based on what has been 
discussed so far, might prove suitable in most cases, 
always keeping in mind patients’ individual situations, of 
course. Figure 1 schematically recapitulates the evidence-
based procedure.
Before initiating biological pharmacotherapy in RA, the 
treating physician may ﬁ  rst start with MTX, considered 
today’s gold standard in the initial treatment algorithm. 
Th   is could be done ﬁ  rst by subcutaneous application of 
15 mg once a week before oral administration, accom-
panied by substitution of folic acid. Discontinu  ation prior 
to any surgical need is not necessary. As higher doses of 
corticosteroids are not required with MTX, it may be 
accompanied by low doses of prednisolone or equivalent. 
Follow  ing re-evaluation after a 6-week period, it is 
possible to increase the amount of MTX up to 30 mg. 
Another 6 weeks later, that is, 3 months after initiating 
therapy, leﬂ  unomide might be added to MTX or be given 
alone. Alternatively, sulfasalazine and hydroxychloro-
quine or cyclosporin A might be added to MTX. After 
another 3 months, biologics can be used, usually 
beginning with TNF antagonists. Whereas inﬂ  iximab and 
golimumab are to be given in combination with MTX, 
however, adalimumab, etanercept and certolizumab may 
replace MTX and could also be administered as 
monotherapy. A combination of leﬂ   uno  mide with an 
anti-TNF agent is also possible. If this strategy fails, a 
second TNF blocker could be tried, although it is 
uncertain if this might be superior and lead to a 
signiﬁ  cant response. Instead, it would also be suitable to 
switch from TNF blockers and use TOZ, RIX or ABC. 
TOZ is also approved to be given without prior trials of 
anti-TNF agents directly after MTX application. RIX may 
be given retentively in patients who are rheumatoid 
factor-negative but shows advantages in rheumatoid 
factor-positive patients. Switching to another biologic 
after RIX does not require the repletion of peripheral B-
cell levels. Similarly, administration of ABC after anti-
TNF treat  ment can be started without waiting for any 
correspond  ing washout. ABC is also licensed for use after 
failure of RIX. To a lesser extent, ANR might also 
represent a possible option in individual treatment plans, 
although its clear value and position within a possible 
pharmaco  therapeutic algorithm of RA require further 
evidence from clinical observations.
Conclusions
Owing to the growing number of pharmacological 
options in treating rheumatic conditions such as RA, it 
has become more important to keep up to date with the 
evidence for the use of novel agents and their roles within 
treatment. When starting to design an individual 
regimen, one has to be cognizant of the following central 
elements: data retrieved from a variety of diﬀ  erent 
Table 1. Current repertoire of biological agents for the treatment of rheumatoid arthritis 
Biological agent  Dose and mode of application  Approved indications
Etanercept (Enbrel®)  25 mg s.c. twice weekly, 50 mg s.c. weekly  Monotherapy, combination therapy
Adalimumab (Humira®)  40 mg s.c. every 2 weeks  Monotherapy, combination therapy
Infl  iximab (Remicade®)  3 mg/kg i.v. every 2 to 4 weeks, then extending intervals up to 8 weeks;   Only in combination with MTX
  maximum dose 5 to 7 mg/kg every 4 weeks
Certolizumab (Cimzia®)  200 mg s.c. every 2 weeks (after loading dose)  Monotherapy, combination therapy
Golimumab (Simponi®)  50 mg s.c. monthly  Only in combination with MTX
Rituximab (MabThera®)  Course of 2 × 500/1,000 mg i.v. with an interval of 2 weeks; several courses   With or without MTX
  every 4 to 8 months possible
Abatacept (Orencia®)  8 to 10 mg/kg i.v. (500 mg (<60 kg), 750 mg (60 to 100 kg), 1 g (>100 kg))   With or without MTX
  at weeks 0, 2, 4, then monthly
Tocilizumab (RoActemra®)  8 mg/kg i.v. monthly   Monotherapy, combination therapy
Anakinra (Kineret®)  100 mg/day s.c.  With or without MTX
I.v., intravenously; MTX = methotrexate; s.c., subcutaneously.
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Page 6 of 10clinical studies; the resulting status of approval; approved 
indications; and post-marketing surveillance data of 
newly available biological agents, also reﬂ  ecting  their 
safety proﬁ  les and their possible interactions with other 
medications and conditions and their side eﬀ  ects  in 
diﬀ   erent patient cohorts comprising individuals with 
diﬀ   erent personal circumstances. Th  e elaboration of 
practical algorithms is intended to help physicians choose 
suitable drugs for therapy routines and for the general 
follow-up of patients and the management of disease 
concomitants. Th   ese should therefore implement 
strategies checking for any complications prior to or 
during drug administration as well as guidelines for 
practical limitations associated with, for example, 
intolerance, comorbidities, surgery, vaccination, preg-
nancy, travel or work. Th   is might add to further unify and 
standardize treatment procedures for patients with RA or 
other rheumatic conditions by reaching even greater con-
sensus, assisting to continuously ameliorate individual 
therapy adaptation and to provide eventual necessary 
interventions without any delay in an optimized system 
of care and disease cure. Fortunately, such procedural 
trends are already well under way [71].
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